FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health
Merck Animal Health, a division of Merck & Co. (MRK), announced FDA approval for BRAVECTO® QUANTUM, a once-yearly injectable treatment for fleas and ticks in dogs. The product, already approved in over 50 countries, offers 12-month protection, longer than existing options. It is expected to be available in the U.S. by August 2025. According to the company, the product sets a new standard in pet care and has won industry awards.
How this was made
The 30-second read
Why it matters
The approval introduces a differentiated, long‑acting product that could capture market share from monthly treatments.
Market read
First‑report regulatory approval for a novel animal‑health product; modest but positive impact on MRK.
What to watch
Potential safety concerns with isoxazoline class may temper adoption.
Background
Merck Animal Health (MSD) announced FDA clearance for Bravecto® Quantum, a once‑yearly injectable flea‑and‑tick treatment for dogs.
Ticker impact
FDA approval of Merck Animal Health's once‑yearly injectable flea‑and‑tick product Bravecto® Quantum.
likely upward pressure as investors price in additional revenue from the injectable.
First‑report FDA clearance for a novel 12‑month parasiticide; market expects incremental sales growth.
Market effects
Strengthens the veterinary pharmaceuticals segment and may boost related animal‑health stocks.
U.S. animal‑health market sees a new premium product, modest impact on broader market.
Adds to Merck's global animal‑health footprint, but limited to niche segment.
Counterpoint
Sales rollout could be slower than expected, limiting near‑term upside.
Key entities
- CompanyMerck & Co., Inc.
Parent company of Merck Animal Health, ticker MRK.
- RegulatorFDA
U.S. Food and Drug Administration, granted approval.
